Business
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2
About this update from Pharvaris N.v.
ZUG, Switzerland , June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS ), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit to be held from July 10-13, 2025 , in Baltimore, Maryland . Details of the presentations are as follows: Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study Presenter: Michael E. Manning , M.D. Format: Poster Presentation, #22 Date, time: Friday, July 11 , 12:30-13:30 ET Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study Presenter: Michael E. Manning , M.D. Format: Poster Presentation, #20 Date, time: Friday, July 11 , 12:30-13:30 ET Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks Presenter: H. Henry Li , M.D., Ph.D. Format: Poster Presentation, #5 Date, time: Friday, July 11 , 12:30-13:30 ET Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study Presenter: Marc A. Riedl , M.D., M.S. Format: Poster Presentation, #23 Date, time: Friday, July 11 , 12:30-13:30 ET Title: Durability of response to a single dose of oral deucrictibant for on-demand treatment of hereditary angioedema attacks Presenter: Joshua S. Jacobs , M.D. Format: Poster Presentation, #9 Date, time: Friday, July 11 , 12:30-13:30 ET Title: Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis Presenter: Mark D. Scarupa , M.D. Format: Poster Presentation, #7 Date, time: Friday, July 11 , 12:30-13:30 ET The posters will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations . About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/ . Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications [email protected] Source: Pharvaris N.V.